---
title: "REGENXBIO Q2 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294998886.md"
description: "Regenxbio (RGNX) is set to report Q2 2026 earnings on August 6th before market open. Consensus estimates project an EPS of -$0.11 and revenue of $96.46 million, reflecting a 352.9% year-over-year increase. Analyst sentiment has shifted negatively recently, with EPS estimates seeing one upward and three downward revisions over the past three months, while revenue estimates have experienced five downward revisions and no upward changes."
datetime: "2026-08-05T18:02:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294998886.md)
  - [en](https://longbridge.com/en/news/294998886.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294998886.md)
generator: "portal-rs"
---

# REGENXBIO Q2 2026 earnings preview

Regenxbio (RGNX) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $96.46M (+352.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. Revenue estimates have seen 0 upward revisions and 5 downward. ...

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)

## Related News & Research

- [REGENXBIO to Participate in Upcoming Investor Conferences | RGNX Stock News](https://longbridge.com/en/news/298308059.md)
- [REGENXBIO (RGNX) Projected to Post Earnings on Thursday](https://longbridge.com/en/news/294335262.md)
- [FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial](https://longbridge.com/en/news/298029915.md)
- [Ameren forecasts 2026 EPS of $5.25-$5.45](https://longbridge.com/en/news/298331518.md)
- [REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS](https://longbridge.com/en/news/295177397.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**